Spektron Systems seeks a few, select strategic partners with which to demonstrate, and share in the value of, Q-MAP’s powerful, AI-based Drug Discovery capacity. Spektron desires to succeed in demonstrations of:
The platform takes a many-models approach to reduce uncertainty in predictions for clinical results. The Q-MAP™ platform shortens discovery timelines from biology to preclinical candidates (PCC) from 4.5+ years to approximately 1 year. Our approach disruptively improves pharmaceutical pipeline success.
Spektron have developed predictive models for virtual screening of molecules on a variety of endpoints toxicity, efficacy, and side-effects. This ability to screen molecules in-silico is available for Spektron’s drug discovery pipeline as well as for our partners.
Dr. David Wolf will be speaking on a panel presentation about AI in Healthcare and Spektron’s unique approach to medicinal molecule design. This invite-only presentation will be attended by investors looking to learn more about AI in this industry. Hosted by IMPACTIVE BioConsult, this presentation appends the 2019 BIO CEO SUMMIT and is being held 7:00 pm at Morgan Stanley.
Dr. David Wolf, the President and Chief Medical Officer for Spektron Systems, sat on the panel with other distinguished speakers talking about Artificial Intelligence. In this backstage interview clip, he about the revolutionary impact that AI is having in many industries. He addresses one of the key components of any good machine learning implementation – “Curation! Curation! Curation!”
We would like to give a big welcome to Iva for joining Spektron full time! Iva is one of our Computational Chemists and a great
Spektron Systems has actively engaged in developing synthesis and test plans on five representative molecules representing designs for an antipsychotic medication. Primarily for the purposes
We’re excited to be presenting our business to the Natural State Angel Association tonight! Bob D’Agostino and Tim Dockins have set up shop for the
Spektron System has submitted a Small Business Innovation Research Phase I grant proposal to the NSF for innovations in Computational Biology and Bioinformatics.
